Abstract

Traumatic spinal cord injuries (SCIs) affect 1.3 million North Americans, producing devastating physical, social, and vocational impairment. Pathophysiologically, the initial mechanical trauma is followed by a significant secondary injury which includes local ischemia, pro-apoptotic signaling, release of cytotoxic factors, and inflammatory cell infiltration. Expedient delivery of medical and surgical care during this critical period can improve long-term functional outcomes, engendering the concept of “Time is Spine”. We emphasize the importance of expeditious care while outlining the initial clinical and radiographic assessment of patients. Key evidence-based early interventions (surgical decompression, blood pressure augmentation, and methylprednisolone) are also reviewed, including findings of the landmark Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). We then describe other neuroprotective approaches on the edge of translation such as the sodium-channel blocker riluzole, the anti-inflammatory minocycline, and therapeutic hypothermia. We also review promising neuroregenerative therapies that are likely to influence management practices over the next decade including chondroitinase, Rho-ROCK pathway inhibition, and bioengineered strategies. The importance of emerging neural stem cell therapies to remyelinate denuded axons and regenerate neural circuits is also discussed. Finally, we outline future directions for research and patient care.

Highlights

  • Traumatic spinal cord injuries (SCIs) have devastating consequences for patients and families

  • Direct lifetime costs can be as high as $1.1–$4.6 million per patient, with over 1.3 million patients affected in North America alone[1,2]

  • We summarize the current standards of care and discuss recent advances in the diagnosis, neuroprotection, prognostication, and regeneration for patients with SCI

Read more

Summary

Introduction

Traumatic spinal cord injuries (SCIs) have devastating consequences for patients and families. Neurological Classification of Spinal Cord Injury; IV, intravenous; MAP, mean arterial pressure; MPSS, methylprednisolone; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; NOGO-A, neurite outgrowth inhibitor-A; OEC, olfactory ensheathing cell; PEG, polyethylene glycol; PNS, peripheral nervous system; RCT, randomized controlled trial; ROCK, rho-associated protein kinase; SBP, systolic blood pressure; SC, Schwann cell; SCI, spinal cord injury; STASCIS, Surgical Timing in Acute Spinal Cord Injury Study; TNF-α, tumor necrosis factor-α. Grant information The author(s) declared that no grants were involved in supporting this work

Foundation CaDR
16. Silver J
22. Resnick DK
33. Bracken MB
Findings
42. Paralysis TMPtC
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call